Thomas Gajewski, MD, PhD is Professor in the Departments of Pathology and Medicine.  He oversees the melanoma oncology clinic, is Leader of the Immunology and Cancer Program at the University of Chicago Comprehensive Cancer Center, and directs the Human Immunologic Monitoring core facility.

His laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote anti-tumor immunity in vivo.  Dr. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies against the disease. He also leads development of immune-based therapies for other cancers, using new laboratory data on how the immune system is regulated to develop novel clinical trials.

Dr. Gajewski has published more than 200 papers on these subjects, has served on numerous NIH grant review panels, is an editor for Cancer Research and Journal for Immunotherapy of Cancer, is on the Program Committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), and is past president of the Society for Immunotherapy of Cancer.  He was recently awarded the first American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy.

As his laboratory work leads to new potential immunotherapies for cancer, Dr. Gajewski is involved with several early biotech companies.  He scientific co-founder of Jounce Therapeutics, and has licensing arrangements with Aduro Biotech and Evelo, a new company focused on the microbiome and cancer.